Access to essential asthma medication for children has become a growing concern for families across the United States. The recent removal of the branded asthma drug Flovent from the market by British drug giant GSK has left many families in a difficult situation. The replacement, an authorized generic form of Flovent, comes at a high cost that is not covered by insurance for many families.
For children with asthma, preventive medication like Flovent is crucial to keep their condition under control and prevent asthma attacks triggered by various factors. However, the high cost of asthma drugs, particularly for the youngest children who require daily inhalers, has become a significant barrier for many families.
